- In September 2022, Bened Life launched Neuralli, a groundbreaking development marking the introduction of the first gut-brain medical probiotic. Designed to support neurological conditions such as Parkinson’s disease and autism spectrum disorder, this innovation aims to enhance mental health care through the gut-brain connection. By offering a novel, non-invasive therapeutic option, Neuralli has the potential to complement existing treatments and promote broader acceptance of microbiome-based interventions in the autism therapy market
- In December 2022, STALICLA, a Swiss clinical-stage biotech company, completed Phase 1b trials for its lead drug candidate STP1, focused on treating neurodevelopmental disorders. This advancement demonstrates the company’s progress in precision medicine, using omics-based approaches to target specific biological subtypes. The success of STP1’s early trials signal promising therapeutic potential and could pave the way for more tailored and effective treatments, contributing to the expansion and scientific credibility of the autism therapy market
